Market capitalization | $42.01m |
Enterprise Value | $38.66m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.34 |
P/S ratio (TTM) P/S ratio | 1.45 |
P/B ratio (TTM) P/B ratio | 8.15 |
Revenue growth (TTM) Revenue growth | 192.24% |
Revenue (TTM) Revenue | $28.93m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | 29 29 |
192%
192%
|
|
Gross Profit | 26 26 |
-
|
|
EBITDA | -1.19 -1.19 |
75%
75%
|
EBIT (Operating Income) EBIT | -1.22 -1.22 |
74%
74%
|
Net Profit | -2.60 -2.60 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InnoCan Pharma Corp. operates as a pharmaceutical tech company. Its segments include: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science. It involves two drug delivery technologies: LPT CBD- loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative and self-care products to promote a healthier lifestyle. The company was founded in October 2017 and is headquartered in Alberta, Canada.
Head office | Canada |
CEO | Iris Bincovich |
Employees | 9 |
Founded | 2018 |
Website | www.innocanpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.